Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company focused on developing innovative biotherapeutics, has announced the appointment of Kristin Stafford as its new Chief Financial Officer (CFO), effective April 1, 2026. This strategic move comes as the company aims to enhance its financial leadership during a pivotal time in its growth trajectory. Ms. Stafford brings over 20 years of experience in the life sciences sector, having previously served as Senior Vice President and Chief Accounting Officer at Royalty Pharma plc. Her extensive background includes roles in strategic planning, capital allocation, and managing complex financial transactions, which are expected to be invaluable as Zymeworks continues to advance its pipeline of novel therapies. In her new role, Ms. Stafford will oversee the company's financial operations and reporting, ensuring alignment with Zymeworks' strategic goals. The company has expressed confidence in her ability to contribute to its mission of delivering innovative solutions for patients with difficult-to-treat diseases. Zymeworks also confirmed that Kenneth Galbraith will continue in his roles as Chair of the Board, Chief Executive Officer, and President, following Ms. Stafford's appointment. The transition in leadership is seen as a positive step towards strengthening the company's financial foundation and operational execution as it navigates the evolving biopharmaceutical landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.